US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Personalis, Inc.

< Previous 1 2 3 4 5 Next >
News headline image
Personalis Reports Second Quarter Results and Recent Highlights
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis to Participate in Upcoming Investor Events
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Reports First Quarter Results and Recent Highlights
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis to Announce First Quarter 2026 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis to Participate in the 25th Annual Needham Virtual Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis Reports Third Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
News headline image
Personalis to Announce Third Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
< Previous 1 2 3 4 5 Next >